Evaxion A/S
EVAX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001828253
No open-market purchases or sales by Evaxion A/S insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $4.93M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Evaxion A/S changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 10 | 10 | 0 |
| Shares | 806.8K | 1.35M | +544.4K (+67.5%) |
| Value | $681.8K | $2.50M | +$1.82M (+266.6%) |
New holders (6)
Institutions that held Evaxion A/S at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Ikarian Capital, LLC | 80,000 | $148.0K | 0.05% |
| Boothbay Fund Management, LLC | 23,728 | $43.9K | 0.00% |
| XTX Topco Ltd | 16,281 | $30.1K | 0.00% |
| UBS Group AG | 6,517 | $12.1K | 0.00% |
| GAMMA Investing LLC | 4,866 | $9.00K | 0.00% |
| Advisor Group Holdings, Inc. | 25 | $46 | 0.00% |
Sold out (6)
Institutions that held Evaxion A/S at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Armistice Capital, LLC | 150,462 | $127.2K |
| Invst, LLC | 50,400 | $42.6K |
| Catalina Capital Group, LLC | 34,864 | $29.5K |
| Millennium Management LLC | 22,541 | $18.8K |
| JPMorgan Chase & Co | 780 | $650 |
| South State Corp. | 4 | $3 |